NEGGRAM
LOE ApproachingNDAORALTABLETPriority Review
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEGGRAM is an oral small-molecule tablet approved in 1964 by Sanofi. The generic name and mechanism of action are not specified in available data. It represents a legacy product from the pre-modern NDA era with established clinical use.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), the commercial team is likely focused on managed decline and patient retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEGGRAM offers limited career growth opportunities given its LOE-approaching status and zero linked job openings. Positions would focus on managed care, legacy product stewardship, and transition planning rather than commercial expansion.
Brand ManagerField Sales
Worked on NEGGRAM at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.